IRD
Opus Genetics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
184.46
P/S
22.80
EV/EBITDA
-6.26
DCF Value
$-0.34
FCF Yield
-10.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
57.4%
Operating Margin
-271.9%
Net Margin
-349.3%
ROE
-452.3%
ROA
-98.7%
ROIC
-90.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.9M | $-16.5M | $-0.19 |
| FY 2025 | $14.2M | $-49.6M | $-0.80 |
| Q3 2025 | $3.1M | $-17.5M | $-0.25 |
| Q2 2025 | $2.9M | $-7.4M | $-0.12 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.52
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.